Zhejiang Hisun Pharmaceutical Co Ltd (SHG:600267) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Hisun Pharmaceutical Co Ltd (600267)
Zhejiang Hisun Pharmaceutical Co Ltd (SHG:600267) has a market capitalization of $1.99 Billion (CN¥13.57 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #6294 globally and #1393 in its home market, demonstrating a -0.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Hisun Pharmaceutical Co Ltd's stock price CN¥11.32 by its total outstanding shares 1198761196 (1.20 Billion). Analyse 600267 cash generation efficiency to see how efficiently the company converts income to cash.
Zhejiang Hisun Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Hisun Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.66 Billion to $1.99 Billion (-1.04% CAGR).
Zhejiang Hisun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Hisun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Zhejiang Hisun Pharmaceutical Co Ltd's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.42x
Zhejiang Hisun Pharmaceutical Co Ltd's market cap is 2.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.66 Billion | $8.77 Billion | $13.57 Million | 0.30x | 196.13x |
| 2016 | $2.22 Billion | $9.73 Billion | -$94.43 Million | 0.23x | N/A |
| 2017 | $2.57 Billion | $10.57 Billion | $13.57 Million | 0.24x | 189.30x |
| 2018 | $1.43 Billion | $10.19 Billion | -$492.47 Million | 0.14x | N/A |
| 2019 | $1.69 Billion | $11.07 Billion | $93.07 Million | 0.15x | 18.12x |
| 2020 | $2.82 Billion | $11.35 Billion | $417.19 Million | 0.25x | 6.76x |
| 2021 | $2.40 Billion | $12.14 Billion | $486.89 Million | 0.20x | 4.92x |
| 2022 | $1.91 Billion | $12.04 Billion | $488.86 Million | 0.16x | 3.90x |
| 2023 | $1.64 Billion | $10.37 Billion | -$93.17 Million | 0.16x | N/A |
| 2024 | $1.46 Billion | $9.79 Billion | $601.18 Million | 0.15x | 2.42x |
Competitor Companies of 600267 by Market Capitalization
Companies near Zhejiang Hisun Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Zhejiang Hisun Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Zhejiang Hisun Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Hisun Pharmaceutical Co Ltd's market cap moved from $2.66 Billion to $ 1.99 Billion, with a yearly change of -1.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.99 Billion | +14.46% |
| 2025 | CN¥1.73 Billion | +19.16% |
| 2024 | CN¥1.46 Billion | -11.32% |
| 2023 | CN¥1.64 Billion | -13.87% |
| 2022 | CN¥1.91 Billion | -20.45% |
| 2021 | CN¥2.40 Billion | -15.06% |
| 2020 | CN¥2.82 Billion | +67.34% |
| 2019 | CN¥1.69 Billion | +18.12% |
| 2018 | CN¥1.43 Billion | -44.41% |
| 2017 | CN¥2.57 Billion | +15.62% |
| 2016 | CN¥2.22 Billion | -16.52% |
| 2015 | CN¥2.66 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Zhejiang Hisun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.99 Billion USD |
| MoneyControl | $1.99 Billion USD |
| MarketWatch | $1.99 Billion USD |
| marketcap.company | $1.99 Billion USD |
| Reuters | $1.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss… Read more